DEFB123
gene geneOn this page
Also known as DEFB-23
Summary
DEFB123 (defensin beta 123, HGNC:18103) is a protein-coding gene on chromosome 20q11.21, encoding Beta-defensin 123 (Q8N688). Has antibacterial activity.
Defensins are cysteine-rich cationic polypeptides that are important in the host immunologic response to invading microorganisms. This antimicrobial protein is secreted and is a member of the beta defensin protein family. Beta defensin genes are found in several clusters throughout the genome, with this gene mapping to a cluster at 20q11.1. Two transcript variants, one protein-coding and the other not, have been found for this gene.
Source: NCBI Gene 245936 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 6 total
- MANE Select transcript:
NM_153324
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:18103 |
| Approved symbol | DEFB123 |
| Name | defensin beta 123 |
| Location | 20q11.21 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | DEFB-23 |
| Ensembl gene | ENSG00000180424 |
| Ensembl biotype | protein_coding |
| OMIM | 616076 |
| Entrez | 245936 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000376309
RefSeq mRNA: 1 — MANE Select: NM_153324
NM_153324
CCDS: CCDS13180
Canonical transcript exons
ENST00000376309 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001470131 | 31450029 | 31450257 |
| ENSE00001906646 | 31440632 | 31440756 |
Expression profiles
Bgee: expression breadth broad, 93 present calls, max score 99.24.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1833 / max 224.1892, expressed in 4 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 183959 | 0.1833 | 4 |
Top tissues by expression
231 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right testis | UBERON:0004534 | 99.24 | gold quality |
| left testis | UBERON:0004533 | 99.21 | gold quality |
| testis | UBERON:0000473 | 96.60 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 88.15 | gold quality |
| adult organism | UBERON:0007023 | 83.78 | gold quality |
| corpus epididymis | UBERON:0004359 | 80.87 | gold quality |
| ileal mucosa | UBERON:0000331 | 76.21 | silver quality |
| tibialis anterior | UBERON:0001385 | 65.37 | silver quality |
| caput epididymis | UBERON:0004358 | 60.25 | gold quality |
| deltoid | UBERON:0001476 | 57.42 | gold quality |
| pancreatic ductal cell | CL:0002079 | 57.11 | silver quality |
| quadriceps femoris | UBERON:0001377 | 54.37 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 54.34 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 54.30 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 54.23 | gold quality |
| kidney epithelium | UBERON:0004819 | 53.93 | gold quality |
| upper arm skin | UBERON:0004263 | 53.52 | gold quality |
| vastus lateralis | UBERON:0001379 | 52.79 | gold quality |
| skin of hip | UBERON:0001554 | 50.64 | silver quality |
| buccal mucosa cell | CL:0002336 | 50.27 | gold quality |
| myocardium | UBERON:0002349 | 50.25 | gold quality |
| biceps brachii | UBERON:0001507 | 49.02 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 47.03 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 45.94 | gold quality |
| muscle tissue | UBERON:0002385 | 45.13 | gold quality |
| cauda epididymis | UBERON:0004360 | 43.95 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 43.55 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 43.37 | gold quality |
| jejunum | UBERON:0002115 | 42.77 | gold quality |
| secondary oocyte | CL:0000655 | 42.57 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-134144 | yes | 1394.21 |
| E-ANND-3 | no | 0.65 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): CTCF
Literature-anchored findings (GeneRIF, showing 1)
- The protein encoded by this gene is thought to display antimicrobial activity. (PMID:15772680)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Defb36 | ENSMUSG00000044863 |
| rattus_norvegicus | Defb36 | ENSRNOG00000088915 |
Paralogs (19): DEFB127 (ENSG00000088782), DEFB129 (ENSG00000125903), DEFB118 (ENSG00000131068), DEFB104A (ENSG00000176782), DEFB104B (ENSG00000177023), DEFB125 (ENSG00000178591), DEFB124 (ENSG00000180383), DEFB119 (ENSG00000180483), DEFB108B (ENSG00000184276), DEFB128 (ENSG00000185982), DEFB131A (ENSG00000186146), DEFB132 (ENSG00000186458), DEFB121 (ENSG00000204548), DEFB134 (ENSG00000205882), DEFB135 (ENSG00000205883), DEFB108C (ENSG00000215371), DEFB116 (ENSG00000215545), DEFB115 (ENSG00000215547), DEFB131B (ENSG00000225805)
Protein
Protein identifiers
Beta-defensin 123 — Q8N688 (reviewed: Q8N688)
Alternative names: Beta-defensin 23, Defensin, beta 123
All UniProt accessions (1): Q8N688
UniProt curated annotations — full annotation on UniProt →
Function. Has antibacterial activity.
Subcellular location. Secreted.
Tissue specificity. Abundant expression in the male reproductive tract only. Abundant expressed in testis and the caput region of epididymis, but low in the corpus region.
Similarity. Belongs to the beta-defensin family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q8N688-1 | 1 | yes |
| Q8N688-2 | 2 |
RefSeq proteins (1): NP_697019* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR025933 | Beta_defensin_dom | Domain |
| IPR050544 | Beta-defensin | Family |
Pfam: PF13841
UniProt features (7 total): disulfide bond 3, splice variant 2, signal peptide 1, peptide 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8N688-F1 | 83.83 | 0.49 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Disulfide bonds (3): 25–52, 32–46, 36–53
Function
Pathways and Gene Ontology
Reactome pathways
2 pathways
| ID | Pathway |
|---|---|
| R-HSA-1461957 | Beta defensins |
| R-HSA-1461973 | Defensins |
MSigDB gene sets: 15 (showing top):
REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_DEFENSE_RESPONSE_TO_GRAM_NEGATIVE_BACTERIUM, chr20q11, GOBP_DEFENSE_RESPONSE_TO_BACTERIUM, GOBP_CELL_KILLING, GOBP_RESPONSE_TO_BACTERIUM, REACTOME_ANTIMICROBIAL_PEPTIDES, GSE13738_RESTING_VS_BYSTANDER_ACTIVATED_CD4_TCELL_UP, GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_INTERSPECIES_INTERACTION_BETWEEN_ORGANISMS, GOBP_DISRUPTION_OF_ANATOMICAL_STRUCTURE_IN_ANOTHER_ORGANISM, GOMF_MEMBRANE_DESTABILIZING_ACTIVITY, REACTOME_DEFENSINS, REACTOME_BETA_DEFENSINS, GSE16385_IFNG_TNF_VS_ROSIGLITAZONE_STIM_MACROPHAGE_DN
GO Biological Process (4): innate immune response (GO:0045087), defense response to Gram-negative bacterium (GO:0050829), defense response (GO:0006952), defense response to bacterium (GO:0042742)
GO Molecular Function (0):
GO Cellular Component (1): extracellular region (GO:0005576)
Reactome top-level categories
Rollup of top-2 pathways:
| Category | Pathways |
|---|---|
| Defensins | 1 |
| Antimicrobial peptides | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| immune response | 1 |
| defense response to symbiont | 1 |
| defense response to bacterium | 1 |
| response to stress | 1 |
| defense response | 1 |
| response to bacterium | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
355 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| DEFB123 | DEFB116 | Q30KQ4 | 672 |
| DEFB123 | DEFB125 | Q8N687 | 628 |
| DEFB123 | DEFB115 | Q30KQ5 | 585 |
| DEFB123 | CHCT1 | Q86WR6 | 571 |
| DEFB123 | DEFB124 | Q8NES8 | 559 |
| DEFB123 | DEFB108B | Q8NET1 | 528 |
| DEFB123 | DEFB128 | Q7Z7B8 | 511 |
| DEFB123 | DEFB129 | Q9H1M3 | 507 |
| DEFB123 | CT45A10 | P0DMU9 | 506 |
| DEFB123 | CCDC160 | A6NGH7 | 449 |
| DEFB123 | DEFB131A | P59861 | 433 |
| DEFB123 | DEFB126 | Q9BYW3 | 427 |
| DEFB123 | SPATA4 | Q8NEY3 | 411 |
| DEFB123 | SLC25A53 | Q5H9E4 | 405 |
| DEFB123 | ZCCHC3 | Q9NUD5 | 400 |
IntAct
2 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| DEFB123 | PFDN6 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (15): CACNA2D1 (Affinity Capture-MS), CACNA2D2 (Affinity Capture-MS), TMEM67 (Affinity Capture-MS), PFDN1 (Affinity Capture-MS), PFDN2 (Affinity Capture-MS), PFDN4 (Affinity Capture-MS), PFDN5 (Affinity Capture-MS), PFDN6 (Affinity Capture-MS), CTBS (Affinity Capture-MS), COL6A2 (Affinity Capture-MS), LDLR (Affinity Capture-MS), LRP4 (Affinity Capture-MS), SORL1 (Affinity Capture-MS), LRP1B (Affinity Capture-MS), VBP1 (Affinity Capture-MS)
ESM2 similar proteins: A3RJ36, A4H1Z9, A4H200, A4H235, A4H236, O02775, O15263, O19038, O19039, O62697, O88514, O97946, P25068, P46156, P46157, P46158, P46165, P46168, P61261, P61262, P80391, P80392, P81534, P83943, Q0E4V3, Q0W9P9, Q28880, Q30KK5, Q30KP9, Q32ZF7, Q32ZF8, Q32ZH7, Q32ZI3, Q32ZI4, Q5J5D0, Q6QLR1, Q6QLR3, Q7JGL8, Q7TNV7, Q7TNV9
Diamond homologs: A4H235, A4H236, Q30KK5, Q30KK6, Q30KL1, Q30KQ4, Q5J5C9, Q5J5D0, Q5J5Z9, Q5J600, Q8K3U4, Q8N688, A4H220, A4H221, A4H222, A4H223, A4H225, A4H226, A4H227, A4H228, Q30KK9, Q30KP9, Q5J602, Q8K3I8, Q8N690, Q95LI0, Q96PH6, Q32ZG3, Q8BGW9, A4H211, A4H212, A4H213, A4H253, A4H254, A4H255, Q30KJ4, Q30KN8, Q32ZG7, Q5IAB3, Q7Z7B8
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
6 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 4 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
199 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 20:31440752:TCCAG:T | donor_loss | 0.9800 |
| 20:31440753:CCAGG:C | donor_loss | 0.9800 |
| 20:31440754:CAGGT:C | donor_loss | 0.9800 |
| 20:31440755:AG:A | donor_loss | 0.9800 |
| 20:31440756:GGTAA:G | donor_loss | 0.9800 |
| 20:31440757:GTA:G | donor_loss | 0.9800 |
| 20:31440758:T:G | donor_loss | 0.9800 |
| 20:31450025:TCA:T | acceptor_loss | 0.9700 |
| 20:31450026:CAGGT:C | acceptor_loss | 0.9700 |
| 20:31450027:A:C | acceptor_loss | 0.9700 |
| 20:31450028:G:C | acceptor_loss | 0.9700 |
| 20:31450016:T:TA | acceptor_gain | 0.9600 |
| 20:31450016:T:A | acceptor_loss | 0.9500 |
| 20:31450028:GGT:G | acceptor_gain | 0.9400 |
| 20:31450023:T:TA | acceptor_gain | 0.9300 |
| 20:31440978:G:GT | donor_gain | 0.9200 |
| 20:31450021:T:A | acceptor_gain | 0.9200 |
| 20:31450027:A:AG | acceptor_gain | 0.9200 |
| 20:31450028:G:GG | acceptor_gain | 0.9200 |
| 20:31450021:T:TA | acceptor_loss | 0.9000 |
| 20:31450027:AGGT:A | acceptor_gain | 0.9000 |
| 20:31450028:GGTG:G | acceptor_gain | 0.9000 |
| 20:31440777:G:GT | donor_gain | 0.7800 |
| 20:31448808:TTC:T | donor_gain | 0.7300 |
| 20:31440759:A:C | donor_loss | 0.6900 |
| 20:31450027:AGGTG:A | acceptor_gain | 0.6900 |
| 20:31450028:GGTGG:G | acceptor_gain | 0.6900 |
| 20:31450025:TCAGG:T | acceptor_gain | 0.6800 |
| 20:31449995:T:TG | acceptor_loss | 0.6700 |
| 20:31450026:CAGG:C | acceptor_gain | 0.6500 |
AlphaMissense
426 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 20:31450048:G:C | W26C | 0.994 |
| 20:31450048:G:T | W26C | 0.994 |
| 20:31450058:G:T | G30C | 0.992 |
| 20:31450124:T:A | C52S | 0.988 |
| 20:31450125:G:C | C52S | 0.988 |
| 20:31450043:T:A | C25S | 0.984 |
| 20:31450044:G:C | C25S | 0.984 |
| 20:31450059:G:T | G30V | 0.984 |
| 20:31450064:T:A | C32S | 0.983 |
| 20:31450065:G:C | C32S | 0.983 |
| 20:31450059:G:A | G30D | 0.981 |
| 20:31450126:C:G | C52W | 0.978 |
| 20:31450106:T:A | C46S | 0.975 |
| 20:31450107:G:C | C46S | 0.975 |
| 20:31450108:C:G | C46W | 0.975 |
| 20:31450107:G:A | C46Y | 0.974 |
| 20:31450076:T:A | C36S | 0.973 |
| 20:31450077:G:C | C36S | 0.973 |
| 20:31450124:T:C | C52R | 0.973 |
| 20:31450127:T:A | C53S | 0.973 |
| 20:31450128:G:C | C53S | 0.973 |
| 20:31450045:C:G | C25W | 0.972 |
| 20:31450125:G:A | C52Y | 0.971 |
| 20:31450043:T:C | C25R | 0.968 |
| 20:31450064:T:C | C32R | 0.965 |
| 20:31450106:T:C | C46R | 0.965 |
| 20:31450125:G:T | C52F | 0.965 |
| 20:31450128:G:A | C53Y | 0.964 |
| 20:31450066:C:G | C32W | 0.962 |
| 20:31450044:G:A | C25Y | 0.961 |
dbSNP variants (sampled 300 via entrez): RS1000418481 (20:31439989 A>T), RS1000534735 (20:31438870 T>G), RS1001215043 (20:31448706 C>CAT), RS1001464290 (20:31446339 A>C), RS1001578778 (20:31446582 T>C), RS1001690792 (20:31441251 C>T), RS1001796608 (20:31447815 C>G,T), RS1001807452 (20:31440088 G>A), RS1002089520 (20:31439897 T>A), RS1002099744 (20:31442697 C>T), RS1002550961 (20:31441432 G>A), RS1002871271 (20:31449636 C>T), RS1004034425 (20:31444512 T>C), RS1004107870 (20:31442765 C>T), RS1004588352 (20:31439364 A>G)
Disease associations
OMIM: gene MIM:616076 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004639_6 | Prudent dietary pattern | 2.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0008111 | diet measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
6 total (human), top 6 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol S | affects cotreatment, decreases methylation | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Arsenic | affects methylation | 1 |
| Benzo(a)pyrene | decreases methylation | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.